An angiogenic switch in macrophages involving synergy between toll-like receptors 2, 4, 7, and 9 and adenosine A2A receptors

American Journal of Pathology

Volumn 163, Issue 2, 2003, Pages 711-721

  Pinhal Enfield, Grace ^a   Ramanathan, Madhuri ^a   Hasko, Gyorgy ^a   Vogel, Stefanie N ^b   Salzman, Andrew L ^c   Boons, Geert Jan ^d   Leibovich, S Joseph ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c INOTEK CORPORATION   (United States)

^d UNIVERSITY OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; ADENOSINE A2A RECEPTOR; ADENOSINE A2A RECEPTOR AGONIST; DNA; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; FLAGELLIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; PACLITAXEL; POLYINOSINIC POLYCYTIDYLIC ACID; RESIQUIMOD; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ELECTROPHORETIC MOBILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; MACROPHAGE; MALE; MASS SPECTROMETRY; MOUSE; NONHUMAN; PORPHYROMONAS GINGIVALIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTON NUCLEAR MAGNETIC RESONANCE; UPREGULATION;

EID: 0041343279     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)63698-X     Document Type: Article

References (77)

1. Ferrara N, Davis-Smyth T: The biology of vascular endothelial growth factor. Endocr Rev 1997, 18:4-25
2. Dvorak HF, Nagy JA, Feng D, Brown LF, Dvorak AM: Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr Top Microbiol Immunol 1999, 237:97-132
3. Leibovich SJ, Chen JF, Pinhal-Enfield G, Belem PC, Elson G, Rosania A, Ramanathan M, Montesinos C, Jacobson M, Schwarzschild MA, Fink JS, Cronstein B: Synergistic up-regulation of vascular endothelial growth factor expression in murine macrophages by adenosine A2A receptor agonists and endotoxin. Am J Pathol 2002, 160:2231-2244
4. Means TK, Golenbock DT, Fenton MJ: Structure and function of toll-like receptor proteins. Life Sci 2000, 68:241-258
5. Underhill DM, Ozinsky A: Toll-like receptors: key mediators of microbe detection. Curr Opin Immunol 2002, 14:103-110
6. Akira S, Takeda K, Kaisho T: Toll-like receptors: critical proteins linking innate and acquired immunity. Nature Immunol 2001, 2:675-680
7. Aderem A, Ulevitch RJ: Toll-like receptors in the induction of the innate immune response. Nature 2000, 406:782-787
8. Hayashi F, Smith KD, Ozinsky A, Hawn TR, Yi EC, Goodlett DR, Eng JK, Akira S, Underhill DM, Aderem A: The innate immune response to bacterial flagellin is mediated by toll-like receptor 5. Nature 2001, 410:1099-1103
9. McDermott PF, Ciacci-Woolwine F, Snipes JA, Mizel SB: High-affinity interaction between gram-negative flagellin and a cell surface polypeptide results in human monocyte activation. Infect Immun 2000, 68:5525-5529
10. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K, Akira S: A toll-like receptor recognizes bacterial DNA. Nature 2000, 408:740-745
11. Bauer S, Kirschning CJ, Hacker H, Redecke V, Hausmann S, Akira S, Wagner H, Lipford GB: Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci USA 2001, 98:9237-9242
12. Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, Horiuchi T, Tomizawa H, Takeda K, Akira S: Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 2002, 3:196-200
13. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA: Recognition of double-stranded RNA and activation of NF-κB by toll-like receptor 3. Nature 2001, 413:732-738
14. Bowie A, O'Neill LA: The interleukin-1 receptor/toll-like receptor superfamily: signal generators for pro-inflammatory interleukins and microbial products. J Leukoc Biol 2000, 67:508-514
15. Van Belle H, Goossens F, Wynants J: Formation and release of purine catabolites during hypoperfusion, anoxia, and ischemia. Am J Physiol 1987, 252:H886
16. Matherne GP, Headrick JP, Coleman SD, Berne RM: Interstitial transudate purines in normoxic and hypoxic immature and mature rabbit hearts. Pediatr Res 1990, 28:348-353
17. Dubyak GR, El-Moatassim C: Signal transduction via P2-purinergic receptors for extracellular ATP and other nucleotides. Am J Physiol 1993, 265:C577-C606
18. Ontyd J, Schrader J: Measurement of adenosine, inosine, and hypoxanthine in human plasma. J Chromatogr 1984, 307:404-409
19. Traut TW: Physiological concentrations of purines and pyrimidines. Mol Cell Biochem 1994, 140:1-22
20. Reinstein LJ, Lichtman SN, Currin RT, Wang J, Thurman RG, Lemasters JJ: Suppression of lipopolysaccharide-stimulated release of tumor necrosis factor by adenosine: evidence for A2 receptors on rat Kuppfer cells. Hepatology 1994, 19:1445-1452
21. Bouma MG, Stad RK, Van der Wildenberg FAJM, Buurman VA: Differential regulatory effects of adenosine on cytokine release by activated human monocytes. J Immunol 1994, 152:4159-4168
22. Hasko G, Szabo C, Nemeth ZH, Kvetan V, Pastores SM, Vizi ES: Adenosine receptor agonists differentially regulate IL-10, TNF-α, and nitric oxide production in RAW 2647 macrophages and in endotoxemic mice. J Immunol 1996, 157:4634-4640
23. Le Moine O, Stordeur P, Schandene L, Marchant A, de Groote D, Goldman M, Deviere J: Adenosine enhances IL-10 secretion by human monocytes. J Immunol 1996, 156:4408-4414
24. Eigler A, Matschke V, Hartmann G, Erhardt S, Boyle D, Firestein GS, Endres S: Suppression of TNF-α production in human mononuclear cells by an adenosine kinase inhibitor. J Leukoc Biol 2000, 68:97-103
25. 2a receptor-dependent and independent mechanisms. EMBO J 2000, 14:2065-2074
26. Fredholm BB, Abbracchio MP, Burnstock G, Daly JW, Harden TK, Jacobson KA, Leff P, Williams M: Nomenclature and classification of purinoreceptors. Pharmacol Rev 1994, 46:143-156
27. Dalziel HH, Westfall DP: Receptors for adenine nucleotides: subclassification, distribution, and molecular characterization. Pharmacol Res 1994, 46:449-466
28. Libert F, Parmentier M, Lefort A, Dinsart C, Van Sande J, Maenhaut C, Simons MJ, Dumont JE, Vassart G: Selective amplification and cloning of four new members of the G-protein-coupled receptor family. Science 1989, 244:569-572
29. Olah ME, Stiles GL: The role of receptor structure in determining adenosine receptor activity. Pharmacol Ther 2000, 85:55-75
30. Folkman J, Hanahan D: Switch to the angiogenic phenotype during tumorigenesis. Princess Takamatsu Symposia 1991, 22:339-347
31. Kandel J, Bossywetzel E, Radvanyi F, Klagsbrun M, Folkman J, Hanahan D: Neovascularization is associated with a switch to the export of bFGF in the multi-step development of fibrosarcoma. Cell 1991, 66:1095-1104
32. Eaves-Pyles T, Murthy K, Liaudet L, Virag L, Ross G, Soriano FG, Szabo C, Salzman AL: Flagellin, a novel mediator of Salmonella-induced epithelial activation and systemic inflammation: iκBα degradation, induction of nitric oxide synthase, induction of proinflammatory mediators, and cardiovascular dysfunction. J Immunol 2001, 166:1248-1260
33. Hirschfeld M, Ma Y, Weis JH, Vogel SN, Weis JJ: Cutting edge: repurification of lipolysaccharide eliminates signaling through both human and murine toll-like receptors. J Immunol 2000, 165:618-622
34. 3Cys-Ser. J Am Chem Soc 1999, 121:7989-7997
35. Kates SA, Albericio F (eds): Solid Phase Synthesis: A Practical Guide. New York, Marcel Dekker, Inc., 2000
36. Kaiser E, Colescott RL, Bossinger CD, Cook PI: Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides. Anal Biochem 1970, 34:595-598
37. Metzger JW, Weismuller KH, Jung G: Synthesis of N α-Fmoc protected derivatives of S-(2, 3-dihydroxypropyl)-cysteine and their application in peptide synthesis. Int J Pept Protein Res 1991, 38:545-554
38. Poltorak A, He X, Smirnova I, Liu M-Y, Van Huffel C, Du X, Alejos E, Silva M, Galanos C, Freudenberg M, Ricciardi-Catsagnoli P, Layton B, Beutler B: Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998, 282:2085-2088
39. Qureshi ST, Lariviere L, Leveque G, Clermont S, Moore KJ, Gros P, Malo D: Endotoxin-tolerant mice have mutations in toll-like receptor 4. J Exp Med 1999, 189:615-625
40. Hoshino K, Takeuchi O, Kawai T, Sanjo H, Ogawa T, Takeda Y, Takeda K, Akira S: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol 1999, 162:3749-3752
41. Schreiber EB, Matthias P, Muller MM, Schaffner W: Rapid detection of octamer binding proteins with "mini-extracts" prepared from a small number of cells. Nucleic Acids Res 1994, 84:3063-3067
42. Feinman R, Koury J, Thames M, Barlogie B, Epstein J, Siegel DS: Role of NF-κB in the rescue of multiple myeloma cells from glucocortocoid-inducec apoptosis by Bcl-2. Blood 1999, 93:3044-3052
43. Ding AH, Porteu F, Sanchez E, Nathan CF: Shared actions of endotoxin and taxol on TNF receptors and TNF release. Science 1990, 248:370-372
44. Manthey CL, Brandes ME, Perera PY, Vogel SN: Taxol increases steady-state levels of lipopolysaccharide-inducible genes and protein-tyrosine phosphorylation in murine macrophages. J Immunol 1992, 149:2459-2465
45. Perera PY, Qureshi N, Vogel SN: Paclitaxel (taxol)-induced NF-κB translocation in murine macrophages. Infect Immun 1996, 64:878-884
46. Cronstein BN: Adenosine, an endogenous anti-inflammatory agent. J Appl Physiol 1994, 76:5-13
47. Heppner G, Weiss DW: High susceptibility of strain A mice to endotoxin and endotoxin-red blood cell mixtures. J Bacteriol 1965, 90:696-703
48. Beutler B, Poltorak A: Positional cloning of Lps, and the general role of toll-like receptors in the innate immune response. Eur Cytokine Netw 2000, 11:145-152
49. Vogel S, Hirschfeld MJ, Perera PY: Signal integration in lipopolysaccharide (LPS)-stimulated murine macrophages. J Endotoxin Res 2001, 7:237-241
50. Hirschfeld M, Weis JJ, Toshchakov V, Salkowski CA, Cody MJ, Ward DC, Qureshi N, Michalek SM, Vogel SN: Signaling by toll-like receptor 2 and 4 agonists results in differential gene expression in murine macrophages. Infect Immun 2001, 69:1477-1482
51. Aliprantis AO, Yang RB, Mark MR, Suggett S, Devaux B, Radolf JD, Klimbel GR, Godowski P, Zychlinsky A: Cell activation and apoptosis by bacterial lipoproteins through toll-like receptor-2. Science 1999, 285:736-739
52. Morrison DC, Jacobs DM: Binding of polymyxin-B to the lipid A portion of bacterial lipopolysaccharides. Immunochemistry 1976, 13:813-818
53. Nemeth Z, Liebovich SJ, Deitch E, Vizi S, Szabo C, Hasko G: cDNA microassay analysis reveals a NF-κB-independent regulation of macrophage function by adenosine. J Pharmacol Exp Ther, in press
54. Wani MC, Taylor HL, Wall ME, Coggon P, McPhali AT: Plant antitumor agents: VI. the isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 1971, 93:2325-2327
55. Schiff PB, Fant J, Horwitz SB: Promotion of microtubule assembly in vitro by taxol. Nature 1979, 277:665-667
56. Schiff PB, Horwitz SB: Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 1980, 77:1561-1565
57. Kirikae T, Ojima I, Fuero-Oderda C, Lin S, Kirikae F, Hashimoto M, Nakano M: Structural significance of the acyl group at the C-10 position and the A ring of the taxane core of paclitaxel for inducing nitric oxide and tumor necrosis factor production by murine macrophages. FEBS Lett 2000, 478:221-226
58. Kawasaki K, Akashi S, Shimuza R, Yoshida T, Miyake K, Nishijima M: Mouse toll-like receptor 4-MD-2 complex mediates lipopolysaccharide-mimetic signal transduction by taxol. J Biol Chem 2000, 275:2251-2254
59. Kawasaki K, Gomi K, Nishijima M: Cutting edge: gln22 of mouse MD-2 is essential for species-specific lipopolysaccharide mimetic action of taxol. J Immunol 2001, 166:11-14
60. Flamme I, Frolich T, Risau W: Molecular mechanisms of vasculogenesis and embryonic angiogenesis. J Cell Physiol 1997, 173:206-210
61. Brown LF, Yeo KT, Berse BK, Yeo TK, Senger DR, Dvorak HF, Van de Water L: Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing. J Exp Med 1992, 176:1375-1379
62. Fehrenbach H, Kasper M, Haase M, Schuh D, Muller M: Differential immunolocalization of VEGF in rat and human adult lung, and in experimental rat lung fibrosis: light, fluorescence, and electron microscopy. Anat Rec 1999, 254:61-73
63. Fava RA, Olsen NJ, Spencer-Green G, Yeo KT, Yeo TK, Berse B, Jackman RW, Senger DR, Dvorak HF, Brown LF: Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J Exp Med 1994, 180:341-346
64. Ferrara N: The role of vascular endothelial growth factor in pathological angiogenesis. Breast Cancer Res Treat 1995, 36:127-137
65. Ladoux A, Frelin C: Hypoxia is a strong inducer of vascular endothelial growth factor messenger RNA expression in the heart. Biochem Biophys Res Commun 1993, 195:1005-1010
66. Goldberg MA, Schneider TJ: Similarities between the oxygen-sensing mechanisms regulating the expression of vascular endothelial growth factor and erythropoietin. J Biol Chem 1994, 269:4355-4359
67. Shima DT, Adamis AP, Ferrara N, Yeo KT, Yeo TK, Allende R, Folkman J, Damore PA: Hypoxic induction of endothelial cell growth factors in retinal cells: identification and characterization of vascular endothelial growth factor (VEGF) as the mitogen. Mol Med 1995, 1:182-193
68. 2, and the three PHDs: how animal cells signal hypoxia in the nucleus. Cell 2001, 107:1-3
69. Semenza GL: HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol 2000, 88:1474-1480
70. 2 tension. Proc Natl Acad Sci USA 1995, 92:5510-5514
71. Stein I, Neeman M, Shweiki D, Itin A, Keshet E: Stabilization of vascular endothelial growth factor mRNA by hypoxia and hypoglycemia and co-regulation with other ischemia-induced genes. Mol Cell Biol 1995, 15:5363-5368
72. Shima DT, Deutsch U, D'Amore PA: Hypoxic induction of vascular endothelial growth factor (VEGF) in human epithelial cells is mediated by increases in mRNA stability. FEBS Lett 1995, 370:203-208
73. Liu LX, Lu H, Luo Y, Date T, Belanger AJ, Vincent KA, Akita GY, Goldberg M, Cheng SH, Gregory RJ, Jiang C: Stabilization of vascular endothelial growth factor mRNA by hypoxia-inducible factor 1. Biochem Biophys Acta 2002, 291:908-914
74. Spychala J: Tumor-promoting functions of adenosine. Pharmacol Ther 2000, 87:161-173
75. Lehr HA, Sagban TA, Ihling C, Zahringer U, Hungerer KD, Blumrich M, Reifenberg K, Bhakdi S: Immunopathogenesis of atherosclerosis: endotoxin accelerates atherosclerosis in rabbits on hypocholesterolemic diet. Circulation 2001, 104:914-920
76. Edfeldt K, Swedenborg J, Hansson GK, Yan ZQ: Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation 2002, 105:1158-1161
77. Li L, Messas E, Batista EL, Levine RA, Amar S: Pophyromonas gingivalis infection accelerates the progression of atherosclerosis in a heterozygous apolipoprotein E-deficient murine model. Circulation 2002, 105:861-867